Evidence map›Paper›PMID 39856748›Full record

ArticleBreast cancer research : BCR2025

Natural killer cells occupy unique spatial neighborhoods in HER2

Femke A I Ehlers, Katie E Blise, Courtney B Betts, Shamilene Sivagnanam, Loes F S Kooreman, E Shelley Hwang, Gerard M J Bos, Lotte Wieten, Lisa M Coussens

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Decoding the breast cancer microenvironment by spatial multi-omics: from architecture to clinical translation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Femke A I EhlersDepartment of Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Center+, Maastricht, 6229, HX, The Netherlands.
Katie E BliseDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, 97239, USA.
Courtney B BettsDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 97239, USA.
Shamilene SivagnanamDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 97239, USA.
Loes F S KooremanGROW - School for Oncology and Reproduction, Maastricht University, Maastricht, 6229 GT, The Netherlands.
E Shelley HwangDepartment of Surgery, Duke University Medical Center, Durham, NC, 27710, USA.
Gerard M J BosDepartment of Internal Medicine, Division of Hematology, Maastricht University Medical Center+, Maastricht, 6229 HX, The Netherlands.
Lotte WietenDepartment of Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Center+, Maastricht, 6229, HX, The Netherlands. l.wieten@mumc.nl.
Lisa M CoussensDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 97239, USA. coussenl@ohsu.edu.

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5M
Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY · 2018 to 2023
$11.4M
Tissue Tension, RANK and Breast Cancer RiskR01CA222508 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HWANG, E.SHELLEY, WEAVER, VALERIE MARIE · 2018 to 2022
$2.8M
Integrated Training in Quantitative and Experimental Cancer Systems BiologyT32CA254888 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Sudarshan Anand, LISA M COUSSENS · 2021 to 2026
$2.2M
NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA222508NCI NIH HHS T32 CA254888NCI NIH HHS U2C CA233254NIH HHS T32CA254888NIH HHS U2CCA233254-01, R01CA222508
6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes are considered clinically beneficial in breast cancer, but the significance of natural killer (NK) cells is less well characterized. As increasing evidence has demonstrated that the spatial organization of immune cells in tumor microenvironments is a significant parameter for impacting disease progression as well as therapeutic responses, an improved understanding of tumor-infiltrating NK cells and their location within tumor contextures is needed to improve the design of effective NK cell-based therapies. In this study, we developed a multiplex immunohistochemistry (mIHC) antibody panel designed to quantitatively interrogate leukocyte lineages, focusing on NK cells and their phenotypes, in two independent breast cancer patient cohorts (n = 26 and n = 30). Owing to the clinical evidence supporting a significant role for NK cells in HER2

Indexed as

Breast NeoplasmsImmunohistochemistryKiller Cells, NaturalLymphocytes, Tumor-InfiltratingAgedBreastCell CountCohort StudiesDisease ProgressionErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunotherapyLymphocyte SubsetsMiddle AgedProteomicsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerImmune contextureMultiplex immunohistochemistryNK cells

Identifiers

PMID39856748
PMCPMC11762118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.